COVID-19 in a patient with SISTEMIC sclerosis: The role of ruxolitinib. (27th September 2021)

• Record Type: Journal Article
• Authors: Ucciferri, Claudio; Auricchio, Antonio; Marinari, Stefano; Vecchiet, Jacopo; Falasca, Katia
• Is Part Of: European journal of inflammation. Volume 19(2021)
• Publication Date: 2021-09-27
• Subjects: SARS-Cov-2 -- Sistemic sclerosis -- ruxolitinib -- anti-JAK; Inflammation -- Periodicals; Anti-Inflammatory Agents -- therapeutic use -- Periodicals; Immunotherapy -- Periodicals; Inflammation -- Periodicals; Anti-inflammatory agents -- Periodicals; Immunotherapy -- Periodicals; Anti-inflammatory agents; Immunotherapy; Inflammation; Periodicals; 616.0473
• DOI: 10.1177/20587392211036813
• Languages: English
• ISSNs: 1721-727X

Abstract

We describe the case of a 78-year-old Italian woman with COVID-19 affected by Systemic Sclerosis with pulmonary fibrosis treated with Ruxolitinib (Ruxolitinib was provided free of charge by Novartis International AG). We chose Ruxolitinib, as a second-line treatment, after administering a standard therapy with hydroxychloroquine and lopinavir/ritonavir, due to a rapid deterioration in the patient's lung function. Ruxolitinib is a janus kinase inibithor with selectivity for subtypes JAK1 and JAK2. A rapid improvement in the patient's respiratory function, objectified with an increase in PO2 /FiO2 value, has been observed in the 10 days after the introduction of Ruxolitinib. Surprisingly we noticed a reduction in pulmonary fibrosis by comparing the chest- CT made before and after the COVID-19 diagnosis. JAK/STAT signalling is involved both in pathogenesis of the second part of COVID-19 and in the modulation of fibrosis in patients with SSc. The use of ruxolitinib should be a new therapeutic option in patients with COVID-19 and lung fibrosis.